Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Adult Participants With Uncontrolled Moderate to Severe Eosinophilic Asthma

NCT07323654 is registered in ClinicalTrials.gov with Kymera Therapeutics, Inc. as lead sponsor.

NCT NCT07323654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07323654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Adult Participants With Uncontrolled Moderate to Severe Eosinophilic Asthma
Lead sponsor
Kymera Therapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
January 28, 2026
Completion date
December 31, 2027
Enrollment
264 (estimated)
Sites
81

Conditions

As the registry lists them; a condition with its own page is linked.

eosinophilic asthma